WB
H
Endogenous
62, 75
Rabbit
#Q96NY8
81607
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human Nectin-4/PVRL4 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Nectin-4/poliovirus receptor-related 4 (PVRL4) is a type-I transmembrane glycoprotein that belongs to the immunoglobulin superfamily and promotes cell-cell adhesion by serving as a major component of adherens junctions (1-3). The extracellular domain of Nectin-4, which contains an Ig variable-like domain (V) and two Ig constant-like domains (C), mediates binding to the measles virus (4) and to neighboring cells through trans heterophilic interactions with Nectin-1 (5,6). Unlike other nectin family members, which are widely expressed in adult tissues, Nectin-4 expression in humans is largely restricted to the placenta (7). Research studies have demonstrated that Nectin-4 is overexpressed in a variety of human solid tumors of the pancreas (8), breast (9,10), lung (11), and ovary (12). Due to its restricted expression pattern in normal human tissues, Nectin-4 may serve as a novel diagnostic and therapeutic target for a variety of human tumors.
- Takai, Y. et al. (2008) Annu Rev Cell Dev Biol 24, 309-42.
- Takai, Y. and Nakanishi, H. (2003) J Cell Sci 116, 17-27.
- Harrison, O.J. et al. (2012) Nat Struct Mol Biol 19, 906-15.
- Mühlebach, M.D. et al. (2011) Nature 480, 530-3.
- Mateo, M. et al. (2014) J Virol 88, 14161-71.
- Fabre, S. et al. (2002) J Biol Chem 277, 27006-13.
- Reymond, N. et al. (2001) J Biol Chem 276, 43205-15.
- Nishiwada, S. et al. (2015) J Exp Clin Cancer Res 34, 30.
- Lattanzio, R. et al. (2014) Oncogenesis 3, e118.
- Fabre-Lafay, S. et al. (2007) BMC Cancer 7, 73.
- Takano, A. et al. (2009) Cancer Res 69, 6694-703.
- Nabih, E.S. et al. (2014) Biomarkers 19, 498-504.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.